Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics

Journal of the American College of Cardiology

Volumn 42, Issue 6, 2003, Pages 1017-1021

  Huizar, Jose F ^a,b   Gonzalez, Luis A ^a   Alderman, James ^c,d   Smith, Harton S ^c,d  

^a METROWEST MEDICAL CENTER   (United States)

^b University Hospital   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Metro West Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CREATINE KINASE; FIBRINOLYTIC AGENT; SULFONYLUREA DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 0042388191     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00916-1     Document Type: Article

References (26)

1. Stamler J, Vacaro O, Neaton JD, et al. Diabetes, other risk factors, and a 12-year cardiovascular mortality, for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.
2. Lazdunski M. Cardiac ATP-sensitive potassium channels: an overview. J Cardiovasc Pharm 1994;24:S1-5.
3. Isomoto S, Kurachi Y. Function, regulation, pharmacology and molecular structure of ATP-sensitive potassium channels in the cardiovascular system. J Cardiovasc Electrophysiol 1997;8:1431-46.
4. Brady P, Terzic A. The suffonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31:950-6.
5. Wilde A. ATP-sensitive potassium channels, transmural ischemia and the ECG implications for the non-insulin dependent diabetic patient? Cardiovasc Res 1996;31:688-90.
6. Kubota I, Yamaki M, Shibata T, et al. Role of ATP-sensitive potassium channel on ECG ST-segment elevation during a bout of myocardial ischemia. Circulation 1993;88:1845-51.
7. Kondo T, Kubota I, Tachibana H, et al. Glibenclamide attenuates peaked T wave in early phase of myocardial ischemia. Cardiovasc Res 1996;31:683-7.
8. Hiraoka M. Pathophysiological functions of ATP-sensitive K channels in myocardial ischemia. Jpn Heart J 1997;38:297-315.
9. Link MS, Wang PJ, VanderBrink BA, et al. Selective activation of the K-ATP channel is a mechanism by which sudden death is produced by low-energy chest wall impact (commotio cordis). Circulation 1999;100:413-8.
10. Szewczyk A. Intracellular targets for antidiabetic sulfonylureas and potassium channel openers. Biochem Pharm 1997;54:961-5.
11. Bajlstra PJ, Russel FG, Thein T, et al. Effects of tolbutamide on vascular ATP-sensitive potassium channels in humans. Horm Metab Res 1996;28:512-6.
12. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischemic preconditioning. Eur Heart J 1999;20:439-46.
13. Crestanello JA, Doliba NM, Babsky AM, et al. Opening of potassium channels protects mitochondrial function from calcium overload. J Surg Res 2000;94:116-23.
14. Sato T, Sasaki N, O'Rourke B, et al. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channel: a key step in ischemic preconditioning? Circulation 2000;102:800-5.
15. Pain T, Yang XM, Critz SD, et al. Opening of mitochondrial K-ATP channels triggers the preconditioned state by generating free radicals. Circ Res 2000;87:460-6.
16. ATP channels with Glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol 1997;79:75-8.
17. Kloner R, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994;24:1133-42.
18. Klimt C, Knatterud GL, Meinert CL, et al. A study of the effects of hypoglycemic agents in vascular complications in patients with adult onset diabetes. Diabetes 1970;19:747-830.
19. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24.
20. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
21. Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 1998;97:709-10.
22. Engler R, Yellon D. Sulfonylurea K-ATP blockade in type II diabetes and preconditioning in cardiovascular disease. Circulation 1996;94:2297-301.
23. Lomuscio A, Fiorentini C. Influence of oral antidiabetic treatment on electrocardiac alterations induced by myocardial infarction. Diab Res Clin Pract 1996;31 Suppl:S21-6.
24. Cacciapuoti F, Spiezia R, Bianchi U, et al. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulins-dependent diabetes mellitus. Am J Cardiol 1991;67:843-7.
25. Bekheit S, Restivo M, Boutjdir M, et al. Effects of glyburide on ischemia-induced changes in extracellular potassium and local myocardial activation: a potential new approach to the management of ischemia-induced malignant ventricular arrhythmias. Am Heart J 1990;119:1025-33.
26. Reeder GS, Kennedy HL. Diagnosis of an acute myocardial infarction. In: Rose B, editor. Wellesley, MA: Up To Date, 2002.